Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance

AbCellera Biologics IncTrade
Schwab US Large Cap Growth ETFTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Schwab US Large Cap Growth ETF — how do they compare? AbCellera Biologics Inc trades at $10.1 (market cap $2.99B), while Schwab US Large Cap Growth ETF trades at $35.6. Which is the better fit depends on your goals.

ABCLSCHG
Market Cap
$2.99B
Sector
HealthSector/Thematic
52-Week High
$9.76$35.83
52-Week Low
$2.78$28.10
Enterprise Value
$2.58B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.

The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.

Schwab US Large Cap Growth ETF

SCHG trades at $35.63, down 0.56% today, with a bullish technical outlook driven by strong moving average signals. The ETF's concentrated exposure to AI leaders like Nvidia and Microsoft positions it for growth, though high RSI readings suggest potential near-term consolidation. Recent news highlights institutional activity and the fund's low 0.04% expense ratio as key advantages.

The outlook remains positive given SCHG's alignment with AI infrastructure growth, but risks include heavy tech concentration and sensitivity to interest rates. Wall Street sentiment is mixed, with some analysts citing valuation concerns while others emphasize long-term growth potential.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Schwab US Large Cap Growth ETF

SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.

Read more on SCHG